What are the normal reference ranges for Luteinizing Hormone (LH) levels in children by age and gender?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

LH Reference Ranges in Children by Age and Gender

I cannot provide the detailed LH reference ranges you requested because the evidence provided does not contain this information—all the guideline documents 1 address lung volumes (FRC, TLC, RV) rather than luteinizing hormone, and one addresses blood pressure monitoring 1.

However, based on the available research studies on pediatric LH levels, here are the age- and gender-specific reference ranges:

Infancy (0-12 months)

Males:

  • 0-3 months: Elevated LH levels, mean approximately 0.5-2.0 IU/L by sensitive IRMA 2, 3
  • 3-12 months: Persistently elevated, gradually declining 3
  • 12-24 months: Declining to prepubertal levels 3

Females:

  • 0-3 months: Lower than males, approximately 0.1-0.5 IU/L 3
  • 3-12 months: Low levels similar to later prepuberty 3
  • 12-24 months: Prepubertal range established 3

Early Prepuberty (Age <8 years)

Both sexes:

  • LH by sensitive IRMA: <0.25 IU/L in 95% of children; ≤0.5 IU/L in remaining 5% 2
  • Urinary LH excretion: Low levels from age 6 months to approximately 6 years 4

Late Prepuberty (Age 8-12 years, Tanner Stage I)

Both sexes:

  • Basal LH: Mean 0.04 ± 0.04 IU/L by ICMA 5
  • LH by IRMA: >0.5 IU/L in 38% of subjects; mean 1.0 ± 1.3 IU/L 2
  • GnRH-stimulated peak LH: 1.8 ± 1.3 IU/L (identical in boys and girls) 5
  • Gradual rise begins: 3-4 years before puberty onset 4

Early Puberty (Tanner Stage II)

Both sexes:

  • Basal LH: >0.5 IU/L in 57% of subjects; mean 1.4 ± 1.3 IU/L 2
  • No significant gender difference in spontaneous LH after infancy 5

Females (Breast Stage II):

  • Significant increment begins at this stage 3

Males (Genital Stage II):

  • LH correlates with testosterone (r=0.76, P<0.001) from late prepuberty through puberty 2

Mid-Puberty (Tanner Stage III)

Both sexes:

  • Basal LH: >1.0 IU/L in 100% of subjects; mean 2.6 ± 1.3 IU/L 2
  • Significantly higher than Stage I (P<0.001) 2

Females (Breast Stage III):

  • Marked increase compared to earlier stages 2

Late Puberty (Tanner Stage IV)

Both sexes:

  • Basal LH: Mean 3.9 ± 2.0 IU/L 2
  • Significantly higher than Stage II (P<0.001) 2

Adult Levels (Tanner Stage V)

Both sexes:

  • Basal LH: Mean 8.6 ± 4.0 IU/L 2
  • Significantly higher than Stage IV (P<0.001) 2
  • GnRH-stimulated peak LH: 20-fold increase from prepubertal levels 5

Females:

  • 38-fold increase from early prepuberty to Stage V 2

Males:

  • 21-fold increase from early prepuberty to Stage V 2

Critical Methodological Considerations

Assay sensitivity is crucial: Older radioimmunoassays (RIA) cannot accurately measure the low LH levels in prepubertal children, showing only 2-4 fold increases across puberty compared to 21-38 fold increases with sensitive IRMA/ICMA methods 2, 5. Use only sensitive immunoassays (IRMA, ICMA, or IFMA) for pediatric LH measurement 2, 5.

GnRH stimulation testing: A peak stimulated LH >5 IU/L by ICMA suggests maturing gonadotropin secretion and pubertal activation 5. Prepubertal children show peak responses of approximately 1.8 IU/L 5.

Clinical utility: Basal LH >0.5 IU/L by sensitive assay can discriminate pubertal from prepubertal status without requiring GnRH stimulation testing in many cases 2, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.